AIM
HZNP

Acrospire Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Acrospire Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-648
Closed -$10K – 2742
2017
Q1 		$10K Sell
648
-19,881
-97% -$322K 0.01% 1875
2016
Q4 		$332K Buy
20,529
+5,800
+39% +$105K 0.14% 110
2016
Q3 		$267K Buy
14,729
+3,800
+35% +$74.2K 0.18% 38
2016
Q2 		$180K Buy
10,929
+5,300
+94% +$85.7K 0.13% 127
2016
Q1 		$93K Buy
+5,629
New +$98.5K 0.06% 382

Other funds holding HZNP

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Acrospire Investment Management's HZNP Position: Q2 2017 in Review

Acrospire Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 648 shares — an estimated $10K sold.

Acrospire Investment Management first reported a position in HZNP in Q1 2016 and held it in 5 quarters. The position peaked at $332K in Q4 2016. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

  • Acrospire Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 648 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $10K.
  • Acrospire Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $332K in Q4 2016.
  • 190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.